Sarepta Therapeutics (SRPT) Accounts Payables (2010 - 2026)

Sarepta Therapeutics' Accounts Payables history runs 17 years deep, the most recent figure standing at $70.4 million for Q1 2026.

• In Q1 2026, Accounts Payables fell 54.92% year-over-year to $70.4 million; the TTM figure through Mar 2026 stood at $70.4 million (down 54.92% YoY), while the FY2025 annual figure was $280.8 million, up 30.96% from the prior year.
• Accounts Payables was $70.4 million for Q1 2026 at Sarepta Therapeutics, down from $280.8 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $280.8 million in Q4 2025 to a low of $54.0 million in Q1 2022.
• Historically, Accounts Payables has averaged $121.4 million across 5 years, with a median of $107.4 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Accounts Payables surged 168.24% in 2022, then sank 54.92% in 2026.
• A 5-year view of Accounts Payables shows it stood at $95.9 million in 2022, then soared by 72.01% to $164.9 million in 2023, then jumped by 30.03% to $214.4 million in 2024, then soared by 30.96% to $280.8 million in 2025, then sank by 74.94% to $70.4 million in 2026.
• The last three Accounts Payables figures came in at $70.4 million (Q1 2026), $280.8 million (Q4 2025), and $94.0 million (Q3 2025), per Business Quant data.